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Malaria eradication: is it possible? Is it worth it? Should we 
do it?
The malaria map is rapidly shrinking. In 1900, endemic 
malaria was present in almost every country. Nowadays, 
the disease has been eliminated in 111 countries and 
34 countries are advancing towards elimination.1 
Elimination is deﬁ ned as the absence of transmission 
in a deﬁ ned geography—typically a country.2 Successful 
malaria control programmes in the remaining 
64 countries with ongoing transmission have helped 
to reduce global incidence by 17% and mortality by 
26% since 2000.3 For the 34 eliminating countries, the 
reductions were 85% in incidence and 87% in mortality.1 
This progress is encouraging, but is worldwide 
eradication of human malaria possible? If so, is it a 
worthwhile goal and should we commit to it? 
Is eradication possible? Probably yes; however, 
substantial challenges exist. First, despite progress, the 
burden of malaria is still great and it is widespread. In 
2010, an estimated 219 million cases of malaria were 
reported and 660 000 people died in 98 countries.3 
Second, drug and insecticide resistance are on the rise. 
In Burma, Cambodia, China, Thailand, and Vietnam, 
resistance of Plasmodium falciparum, the major human 
malarial parasite species, to artemisinin, the most 
widely used ﬁ rst-line drug, has been detected and could 
be spreading despite eﬀ orts to contain it.3,4 Resistance 
to pyrethroid insecticides can happen quickly and has 
emerged after large-scale distributions of bednets in 
several regions.5 Although new drugs and insecticides 
are being sought, none are expected to be available in 
the near future. Third, increased mobility of people not 
only makes containment of resistance diﬃ  cult, but also 
threatens the introduction or reintroduction of malaria 
parasites to receptive areas. Fourth, outside sub-Saharan 
Africa, Plasmodium vivax, the second major human 
malarial parasite species, is the main challenge. P vivax is 
much less researched than is P falciparum. P vivax is harder 
to diagnose and failure to successfully treat its dormant 
liver stage results in relapses that can fuel onward 
transmission. Furthermore, in Borneo and neighbouring 
regions, evidence now exists of human infection by a 
monkey parasite species, Plasmodium knowlesi. Zoonotic 
reservoirs challenge all campaigns for eradication of 
human infection. Fifth, extreme events, such as wars 
or natural disasters, greatly disrupt malaria control 
and elimination activities, and can lead to substantial 
resurgence. When accompanied by large population 
movements, these events can introduce malaria into 
previously malaria-free areas. Sixth, as malaria becomes 
rare, persuasion of governments to allocate ﬁ nances 
to maintain eﬀ ective elimination or post-elimination 
programmes is increasingly diﬃ  cult. Since 1930, 
75 resurgences of malaria have been recorded and 
nearly all are linked to the scaling back of programmes.6 
These six factors present notable challenges on the road 
to eradication. However, all have potential solutions 
resulting from substantial international collaborative 
eﬀ orts that range from basic research to improvements 
in policy and ﬁ nancing arrangements.
Is eradication worth it? Probably yes, but the answer is 
dependent on the temporal and spatial perspective. From 
a temporal perspective, the cost–beneﬁ t ratio is dependent 
on whether the comparison is between rampant and no 
malaria, or between low and no malaria. For rampant 
versus no malaria, the eﬀ ort is hugely cost beneﬁ cial. 
However, for a comparison between low and no malaria, 
and if only the costs and beneﬁ ts of the last mile are 
examined, the outcome is less certain and the costs and 
beneﬁ ts might be more evenly balanced. From a spatial 
perspective, a country that eliminates malaria confers 
substantial beneﬁ ts on its neighbours and on other 
countries that no longer are at risk of malaria importation. 
Additionally, a country that successfully eliminates moves 
the entire world closer to eradication. Thus, there are 
regional and global public-good dimensions to the eﬀ orts 
of any individual country. Quantiﬁ cation of these public 
goods is challenging, but they certainly exist and add to 
the beneﬁ t side of the equation. 
Should we eradicate malaria? Yes, because the 
alternative policies are untenable. If the world is not going 
to commit to progressive elimination leading to eventual 
global eradication, what is it going to commit to? Imagine 
a world in which the goal was merely to control malaria—
ie, reduce it to a level at which it is no longer a major public 
health problem. In countries with good malaria control, 
pockets of malaria will be left in poor and marginalised 
populations, whereas in other regions, like the humid 
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tropics of Africa, control programmes will struggle to 
keep malaria cases and deaths low. The remaining parasite 
reservoirs are likely to become drug-resistant and the local 
vectors insecticide-resistant. These enduring pockets will 
be the source of malaria that is introduced into receptive, 
malaria-free areas elsewhere. Thus, malaria-free countries 
will need to continually maintain expensive vigilance and 
response programmes to prevent resurgence of drug-
resistant parasites.
Such a situation will be expensive, unstable, and is 
an unappealing policy option for the 21st century. The 
practical policy option, and the one that will be less costly 
in the long term, is to pursue a global policy of progressive 
elimination, aggressive control in the high-burden 
areas, and eventual eradication. This policy is even more 
appealing in consideration of recent evidence showing 
that malaria elimination could be an inherently stable 
state, unlike sustained control.7,8 No-one can know 
when malaria will be eradicated. Our estimate is perhaps 
2050 or 2060. The last battles will likely be waged in 
wet, tropical, and poor areas: against P falciparum in 
sub-Saharan Africa and P vivax in Melanesia. Continued 
vigilance will be needed against zoonotic malaria arising 
from close human–macaque contact in Borneo and 
neighbouring areas.9 Special measures will need to be 
designed and implemented to control such malaria. 
An important driver of the eradication scenario is 
research. Thanks to the Bill & Melinda Gates Foundation, 
the US National Institutes for Health, the Wellcome 
Trust, and others, research in malaria is more vibrant 
than it has been at any point in the past 50 years. New 
drugs are in development. Discovery of single-dose 
drugs that will cure both P falciparum and P vivax is a 
real possibility. The ﬁ rst malaria vaccine, RTS,S/AS01 is 
likely to be launched in 2015. The eﬃ  cacy of the vaccine 
is modest, but it could make a useful contribution in 
reducing malaria in children in high-burden settings and 
in adults in elimination settings.1 Development of this 
vaccine also starts a journey towards other and better 
vaccines. Diagnostics have improved substantially and 
rapid diagnostic tests have already replaced microscopy 
in many countries. Within a few years, portable and 
ﬁ eld-friendly molecular testing kits could be available 
that could identify all Plasmodium species at very low 
densities. Renewed eﬀ orts are underway to identify new 
classes of insecticides. Each of these developments will 
make a huge contribution to malaria eradication. 
From roughly 1980 to 2007, speaking of elimination 
and eradication in connection with malaria was regarded 
as naive and overambitious. However, speeches by 
Bill and Melinda Gates on Oct 17, 2007,10 calling for 
nothing less than global malaria eradication, radically 
changed this dynamic. Since then, there has been an 
upsurge of commitment to elimination and eventual 
eradication, and these concepts are now mainstream in 
the international malaria community and embraced by 
the Roll Back Malaria Partnership and by WHO.11
Of the ten leading causes of death in the developing 
world, malaria is the only one with a real prospect 
for eradication.12 Progress is good. Our weapons are 
eﬀ ective and continually improving. With adequate and 
sustained commitment, the task can be achieved. 
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